ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,296.72
0.59%
Dow Jones
39,112.16
-0.76%
Gold vs US Dollar
2,316.53
-0.18%
Brent Oil
84.495
0.37%
Bitcoin
61,446.85
-0.59%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Pasithea Therapeutics Corporation (KTTA) Share Price

KTTA Pasithea Therapeutics Corporation

5.30
0.00 (0.00%)
Pre Market
Last Updated: 09:05:40
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Pasithea Therapeutics Corporation NASDAQ:KTTA NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.00 0.00 5.30 2.12 5.75 0.00 0.00   08:05:40   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations  -15.96M -15.3003 -0.35 5.53M
 Type  Size  Price  Time  Units 
   0.00  
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore KTTA News
13/06/202411:59GLOBEPasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial
28/05/202411:59GLOBEPasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
29/04/202412:59GLOBEPasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
24/04/202412:59GLOBEPasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
02/03/202402:46EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
02/03/202402:46EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
02/03/202402:46EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
Period
Draw mode
Data Downloads for KTTA

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Pasithea Therapeutics Corporation Articles